PCM
ETNB

Prelude Capital Management’s 89bio ETNB Stock Holding History

Prelude Capital Management’s Portfolio ETNB Stock Details ETNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-92,955
Closed -$1.37M – 1369
2025
Q3 		$1.37M Buy
92,955
+22,568
+32% +$230K 0.11% 239
2025
Q2 		$691K Sell
70,387
-27,700
-28% -$229K 0.07% 356
2025
Q1 		$713K Buy
98,087
+29,086
+42% +$254K 0.05% 402
2024
Q4 		$540K Sell
69,001
-26,499
-28% -$218K 0.03% 572
2024
Q3 		$707K Buy
+95,500
New +$803K 0.04% 493
2023
Q4 		– Sell
-13,400
Closed -$207K – 1182
2023
Q3 		$207K Buy
13,400
+2,168
+19% +$36.4K 0.01% 884
2023
Q2 		$213K Buy
+11,232
New +$197K 0.01% 822

Other funds holding ETNB

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's ETNB Position: Q4 2025 in Review

Prelude Capital Management sold out of 89bio (ETNB) in Q4 2025, closing a stake of 92,955 shares — an estimated $1.37M sold.

Prelude Capital Management first reported a position in ETNB in Q2 2023 and held it in 7 quarters. The position peaked at $1.37M in Q3 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • Prelude Capital Management reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 92,955 89bio shares in Q4 2025, an estimated $1.37M.
  • Prelude Capital Management first reported a position in 89bio in Q2 2023 and held it in 7 quarters.
  • Prelude Capital Management's 89bio position peaked at $1.37M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.